LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, provides further details regarding the transactions by persons discharging managerial responsibilities (“PDMRs”) in connection with the $200 million Financing announced earlier today.
Capitalised terms in this announcement have the same meanings to those defined in the Financing announcement which was released at 7.00 a.m. on July 17, 2020, unless otherwise indicated.PDMR PurchasesVerona Pharma notifies the following transactions by PDMRs in its Ordinary Shares or ADSs through participation in the Financing.The Company notes that participation of Mr Vikas Sinha as disclosed in the Financing announcement is not required to be notified as a PDMR dealing as the subscription was not made by Mr Sinha, nor any persons closely associated with him (in accordance with the definitions under MAR) but was made by the trustees of certain family members of Mr Sinha.For further information, please contact:
Bay Street News